Evidence map›Paper›PMID 36139534›Full record

ArticleCancers2022

MicroRNA-769-3p Acts as a Prognostic Factor in Oral Squamous Cell Cancer by Modulating Stromal Genes.

Heejin Lee, Sang Hoon Chun, Seo Yun Moon, Jung-Sook Yoon, Hye Sung Won, Soon Auck Hong, Seo Ree Kim, Kwang-Jae Cho, Keunsoo Kang, Sieun Lee and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. miRNA in head and neck squamous cell carcinomas: promising but still distant future of personalized oncology.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Heejin LeeDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Sang Hoon ChunCancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.ORCID 0000-0002-5847-7317
Seo Yun MoonDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Jung-Sook YoonUijeongbu St. Mary's Hospital Clinical Research Laboratory, The Catholic University of Korea, Uijeongbu-si 11765, Korea.
Hye Sung WonCancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.ORCID 0000-0002-5134-4538
Soon Auck HongDepartment of Pathology, College of Medicine, Chung-Ang University, Seoul 06973, Korea.ORCID 0000-0002-7902-4608
Seo Ree KimDivision of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Kwang-Jae ChoDepartment of Otolaryngology-Head and Neck Surgery, The Catholic University of Korea College of Medicine, Seoul 06591, Korea.
Keunsoo KangDepartment of Microbiology, College of Science & Technology, Dankook University, Cheonan 31116, Korea.
Sieun LeeDepartment of Molecular Medicine, College of Medicine, Ewha Womans University, Seoul 07804, Korea.
Young-Ho AhnDepartment of Molecular Medicine, College of Medicine, Ewha Womans University, Seoul 07804, Korea.ORCID 0000-0002-1084-0367
Ji Hyung HongCancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.ORCID 0000-0002-0492-3959
Yoon Ho KoCancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.ORCID 0000-0002-2506-3740

Funding

an industry-academic co-operation research fund from the Catholic University of Korea 5-2020-D0403-00001Basic Science Research Program through the National Research Foundation funded by the Min-istry of Education NRF-2020R1I1A1A01066968the Catholic University of Korea Uijeongbu St. Mary's Hospital Clinical Research Laboratory Foundation UJBCRL201840
6 · The paper itself

Abstract

miR-769-3p expression is suppressed in the stromal subtype of head and neck squamous cell carcinoma (HNSCC); however, its role in stromal HNSCC has not been fully elucidated. To investigate the biological relevance of miR-769-3p in the stromal phenotype, we established oral squamous cell cancer (OSCC) cell lines, namely CAL27, HSC3, and YD8, overexpressing miR-769-3p. miR-769-3p expression was positively and negatively correlated with interferon-gamma-related genes and MYC target gene sets, respectively. miR-769-3p decreased OSCC cell migration and invasion as well as mesenchymal marker expression and increased epithelial marker expression. Moreover, miR-769-3p enhanced OSCC cell sensitivity to 5-fluorouracil. High miR-769-3p expression was associated with good prognosis of HNSCC patients. Collectively, these results suggest that miR-769-3p suppression enhances stromal gene expression and promotes the epithelial-to-mesenchymal transition. Therefore, miR-769-3p may be a potential biomarker of the miRNA phenotype in OSCC patients.

Indexed as

EMThead and neck neoplasmmiR-769stromatumor-suppressive

Identifiers

PMID36139534
PMCPMC9496693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.